Targeting of Interleukin-13 Receptor a2 for Treatment of Head and Neck Squamous Cell Carcinoma Induced by Conditional Deletion of TGF-ß and PTEN Signaling
|
Research Initiative
|
FDA
|
NIDCD, NIDCR
|
2010
|
|
Task Force on Environmental Health Risks and Safety Risks to Children: Coordinated Federal Action Plan to Reduce Racial and Ethnic Asthma Disparities
|
Meeting/ Workshop
|
ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, OSG
|
NCMHD, NHLBI, NIAID, NICHD, NIEHS, NINR
|
2009
|
|
Ten years post PKU Consensus Conference: State of the Science (committee)
|
Other
|
AHRQ, CDC, FDA, HRSA
|
NHGRI, NICHD, NIDDK, NINDS
|
2009
|
|
Text 4 Baby Program Evaluation Technical Advisory Group
|
Advisory Group
|
CDC, FDA, HRSA, OS, SAMHSA
|
NICHD
|
2010
|
|
The Federal Tuberculosis Task Force
|
Other
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS, SAMHSA
|
FIC, NCATS, NHLBI, NIAAA, NIAID, NICHD, NIDA
|
1991
|
|
The Foundation for the NIH Biomarkers Consortium
|
Research Initiative
|
CMS, FDA
|
NCI, NHLBI, NIA, NIAID, NIAMS, NIBIB, NICHD, NIDDK, NIMH, NINDS
|
2006
|
|
The Health Effects of Sodium Reduction
|
Other
|
CDC, FDA
|
NHLBI, NIDDK
|
2011
|
|
The NIH Bone Marrow Stromal Cell Transplantation Center (BMSC)
|
Research Initiative
|
FDA
|
CC, NCI, NHLBI, NIAID, NIAMS, NIBIB, NIDCR, NINDS
|
2009
|
|
The Pharmacology Research Associate (PRAT) Program
|
Training Initiative
|
FDA
|
NIGMS
|
1965
|
|
The Science of Sex and Gender in Human Health
|
Advisory Group
|
FDA
|
OD/ DPCPSI/ ORWH
|
2006
|
|
The Trans-NIH Rare Diseases Working Group
|
Advisory Group
|
FDA
|
CC, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM
|
2004
|
|
Therapeutics for Rare and Neglected Diseases (TRND)/FDA Working Group
|
Advisory Group
|
FDA
|
CC, NCATS, NICHD, NINDS
|
2009
|
|
Think Tank on the Identifiability of Biospecimens and “-Omic” Data
|
Meeting/ Workshop
|
FDA, OS
|
NCI, NHGRI
|
2012
|
|
Third Pan-American Dengue Research Network Meeting
|
Meeting/ Workshop
|
CDC, FDA
|
NIAID
|
2012
|
|
Tobacco and Nicotine Research Interest Group (TANRIG)
|
Other
|
CDC, FDA, SAMHSA
|
NCI, NHGRI, NHLBI, NIAAA, NIAID, NICHD, NIDA, NIEHS, NIMH, NINR, OD/ DPCPSI/ OBSSR
|
2003
|
|
Tobacco Policy Modeling Workshop
|
Meeting/ Workshop
|
FDA
|
NCI, NIDA, OD/ DPCPSI/ OBSSR
|
2012
|
|
Tobacco Product Interagency Agreement
|
Other
|
FDA
|
NCI
|
2012
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
NCI, OD/ DPCPSI/ ODP, OD/ OER
|
2012
|
|
Tobacco Training Workgroup Subgroup of the NIH-FDA Tobacco Regulatory Science Workgroup
|
Advisory Group
|
FDA
|
NCI, NICHD, NIDA, NIDCD, NIDCR, NIEHS, NIGMS, NIMH, NINDS, NINR, NLM, OD/ DPCPSI/ OBSSR
|
2011
|
|
Toxicology in the 21st Century (Tox21) Program
|
Research Initiative
|
FDA
|
NCATS, NIEHS
|
2008
|
|
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
|
Other
|
CDC, FDA, OS
|
NIAID
|
2009
|
|
Trans-NIH Plan for HIV-Related Research
|
Advisory Group
|
CDC, FDA, HRSA, OS
|
CC, CSR, FIC, NCATS, NCCAM, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/ DPCPSI/ OAR, OD/ DPCPSI/ ORIP, OD/ DPCPSI/ ORWH
|
1994
|
|
Treating for Two: Safe Medication Use in Pregnancy Initiative
|
Advisory Group
|
AHRQ, CDC, FDA, HRSA
|
NICHD, OD/ DPCPSI/ ORWH
|
2012
|
|
|